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No study has ever examined the eﬀect of vitamin C with metformin on fasting (FBS) and postmeal blood glucose (PMBG) as well
as glycosylated hemoglobin (HbA1c) in the treatment of type 2 diabetes mellitus (DM). The goal was to examine the eﬀect of
oral vitamin C with metformin on FBS, PMBG, HbA1c, and plasma ascorbic acid level (PAA) with type 2 DM. Seventy patients
with type 2 DM participated in a prospective, double-blind, placebo-controlled, 12-week study. The patients with type 2 DM were
divided randomly into placebo and vitamin C group of 35 each. Both groups received the treatment for twelve weeks. Decreased
PAA levels were found in patients with type 2 diabetes mellitus. This level was reversed signiﬁcantly after treatment with vitamin
C along with metformin compared to placebo with metformin. FBS, PMBG, and HbA1c levels showed signiﬁcant improvement
after 12 weeks of treatment with vitamin C. In conclusion, oral supplementation of vitamin C with metformin reverses ascorbic
acid levels, reduces FBS, PMBG, and improves HbA1c. Hence, both the drugs in combination may be used in the treatment of type
2 DM to maintain good glycemic control.
1.Introduction
Diabetes mellitus (DM) is one of the major metabolic disor-
ders associated with great deal of morbidity and economic
cost. Apart from hyperglycemia, DM is also characterized
by oxidative stress, inﬂammation, and insulin resistance [1].
Several investigators have implicated the role of free radical-
mediated pathology in diabetes mellitus [2, 3]. The illness
has poor outcome in spite of the best currently avail-
able treatments. Hence, development of novel strategies to
improve the outcome will be of great beneﬁt. Presently
available oral hypoglycemic agents do not show marked
improvement in oxidative stress in diabetic patients [4].
Ascorbic acid (vitamin C), an antioxidant vitamin, plays an
important role in protecting free radical-induced damage.
Previous study has shown decrease in basal vitamin C level
in type 2 DM [5]. Vitamin C is structurally similar to glucose
and can replace it in many chemical reactions and thus is
eﬀective for prevention of nonenzymatic glycosylation of
protein [6].
Up-to-date, available literature suggests conﬂicting re-
sults related to supplementation of vitamin C and improve-
ment in blood glucose level and glycosylated hemoglobin
(HbA1c) [7, 8]. However, no study has ever examined the ef-
fects of vitamin C with metformin in the treatment of type 2
diabetes mellitus, especially on postmeal blood glucose
(PPBG) level. Recent study reported reduction in fasting
blood glucose (FBG) and glycosylated hemoglobin after sup-
plementation with vitamin C, but it was an open-label, non-
controlled, and short duration study [5]. Therefore, it was
considered worthwhile to measure the eﬀect of vitamin C
along with metformin on levels of FBG, PPBG, HbA1c, and
plasma ascorbic acid in a double-blind, controlled study for
longer duration in patients with type 2 diabetes mellitus.2 Advances in Pharmacological Sciences
2.MaterialsandMethods
2.1. Patients, Inclusion, and Exclusion Criteria. Seventy pa-
tients with type 2 diabetes mellitus participated in a prospec-
tive, double-blind, placebo-controlled, noncrossover, 12-
week study approved by Institutional Ethics Committee of
Indira Gandhi Government Medical College, Nagpur, India.
All patients gave their informed consent prior to their inclu-
sion in the study. The inclusion criteria were patients from
Outpatient Department (OPD) of Medicine and diagnosed
patients of type 2 DM of age group between thirty to sixty
years who were on metformin and having fasting blood
glucose level in the range of 126 to 250mg/dL. Exclusion
criteria for patients were fasting blood glucose level more
than250mg/dL,medicalillnessesincluding otherendocrine,
metabolic, type 1 DM, pregnancy, isolated postprandial
hyperglycemia, and age more than 60 years or less than
30 years. None of the subjects was a regular drinker, heavy
smoker, or had been taking any psychotropic drug. Routine
investigations like electrocardiogram, serum electrolytes,
blood urea, serum certainties, and liver function test were
performedtoruleoutactivemedicalproblemsinallpatients.
Patients who have received vitamin C or any other antioxi-
dant over the last three months were also excluded from the
study. The period of the present study was from February
2009 to November 2010.
2.2. Sample Size, Randomisation, and Treatment. Patients
with type 2 DM were divided randomly into two groups, A
and B of 35 each. Sample size was calculated with standard
deviation taken from the previous study and level of signif-
icance at 0.05 with power as 80%. Block randomization
procedure was used for random allocation of study drugs,
that is, vitamin C and placebo with blocks of size 4 in
equal proportions to ensure uniform allocation ratio (1:1).
The study being double-blind, the drugs were identical in
formulation, shape, size, weight, texture, and packing. The
randomized treatment allocation sequence was generated by
statistician using random number table. It was handed over
along with identical plastic containers ﬁlled with the study
drugs (sixty each of vitamin C and placebo) to a third person
not directly involved in this study. This person labelled the
containers according to the random allocation sequence
of patients with drugs provided. The code of this random
allocation sequence was retained in the sealed envelope by
this person and was opened only after the completion of
study during analysis of the data. The patients as well as the
investigators were unaware of the treatment (Vitamin C or
placebo) being administered. Drug was issued to patients for
duration of thirty days at a time. Patients were asked to bring
the unused drugs and container during the followup. Ninety
percent consumption was considered to be compliant. The
return drugs were discarded. Drugs were decoded at the end
of trial. Group A received vitamin C with metformin and
group B received placebo along with metformin. The dose of
vitamin C was 500mg twice a day and decided on the basis
of previous study. All patients received open label tablet
metformin 500mg twice daily orally with lunch and dinner,
as it is unethical to give either only placebo or vitamin C to
diabetes patients. These patients, who were on metformin,
were not on any other medicine including other antidiabetic
agents. The intake of metformin did not start at the same
time as the intake of vitamin C because the patients were on
metformin for variable period within 0 to 6 months but not
more than 6 months.
In our preliminary experiment, it was determined that
subjects reached a new lower steady-state plasma concentra-
tion after one week on controlled diet. Placebo or vitamin
C supplementation was started after one week of vitamin C
restricted diet. Patients were given a new supply of tablets at
the end of each fourth week. Same doses were maintained
throughout the study. Patients were not stabilised before en-
rolment in the study as they were satisfying our main in-
clusion criteria. But if we ﬁnd increased fasting blood sugar
levelbeyond250duringthestudyperiod,thenweexcludthat
patient from the study. No comorbid condition or infection
occurred to these study patients during the study period.
After study period was over, subjects were handed over to
respective physician.
2.3. Diet and Investigations. All patients were maintained on
their usual dietary pattern while limiting their consumption
of vitamin C-rich foods throughout the study. As patients
were on self-selected diet, each patient was instructed by
a dietician to use comprehensive food list that contained
food items by type, portion size, method of preparation, and
vitamin C content. This enabled patients to substitute foods
with low-vitamin content for those patients who normally
consume higher levels of vitamin C and also to ensure that
their daily intake from dietary sources would remain the
same. Compliance to dietary restrictions of ascorbic acid
was determined by obtaining a 24hr dietary recall from the
subjects during each month period. Fasting, postmeal blood
glucose, glycosylated hemoglobin, plasma ascorbic acid, and
liver and kidney function tests were repeated after twelve
weeks. Fasting blood samples were obtained at baseline
for the assessment of fasting, glycosylated hemoglobin, and
plasma ascorbic acid (one week after vitamin C-restricted
diet), whereas postmeal blood samples were taken for
assessment of postmeal blood glucose 2 hours after meal.
General clinical safety was monitored by vigilant followup
of patients for treatment of emergent adverse events, if any,
and recorded in the case report form. Patients with adverse
drug reaction were treated appropriately by the physician
in medicine OPD. Plasma ascorbic acid was estimated
by a single-step calorimetric method using modiﬁed acid
phosphotungstate reagent [9]. Supernatant was used to
measure absorbance at 700nm. Standards of pure ascorbic
acid obtained from Sigma Company, USA, in the range of
0.10to0.90mg%werepreparedin0.5%oxalicacidsolution.
For all the investigations, chemicals used were of analytical
reagent grade. Fasting as well as postprandial blood glucose
level and HbA1c was quantitatively estimated by glucose
oxidase method and cation-exchange resin method with
the use of semiautoanalyser, TRANSASIA, ERBA, CHEM-5
PLUS, respectively.Advances in Pharmacological Sciences 3
2.4. Statistical Analysis. Results were expressed as Mean ±
standard error of mean (SEM). Group diﬀerences were
ascertained by either paired or unpaired t-test. Relationship
between variables was determined by means of either
Pearson’s or Spearman’s correlation coeﬃcient depending
on distribution of the data. Chi-square test was used
for analysis of demographic data. Two-tailed P value was
used throughout, and the P values less than 0.05 were
adjudged statistically signiﬁcant. GraphPad Prism version
5.00 software was used for analysis.
3. Results
The mean age of the patients with diabetes mellitus in
v i t a m i nCg r o u p( 4 8 .33 ± 1.39 years) and placebo group
(45.88±1.42 years) was not signiﬁcantly diﬀerent from each
other (Table 1). Fasting, postmeal blood glucose, and plasma
ascorbic acid levels did not diﬀer among subjects before
receiving placebo and vitamin C treatment (P>0.05).
In placebo group, levels of fasting and postmeal blood
glucose reduced signiﬁcantly (P<0.05), and at the same
time, levels of plasma ascorbic acid increased after 12
weeks of treatment compared to pretreatment levels but
was nonsigniﬁcant. Reduction in glycosylated hemoglobin
was seen but it did not reach to statistically signiﬁcant
level (Table 2). In patients receiving vitamin C, reduction
in fasting and postmeal blood glucose was signiﬁcant at
week twelve. In contrast, plasma ascorbic acid levels raised
signiﬁcantly after twelve weeks of treatment. Simultaneously
after twelve weeks, signiﬁcant reduction was observed in
glycosylated hemoglobin (Table 3).
To test whether oral supplementation of vitamin C is
better in reversing fasting, postmeal blood glucose, and gly-
cosylated hemoglobin as compared to placebo, we compared
eﬀects of drugs in placebo and vitamin C group after 12
weeks of treatment, taking into consideration the change
from baseline values of these parameters. Decrease in fasting
and postmeal blood glucose level was signiﬁcant after twelve
w e e k si nv i t a m i nCg r o u pc o m p a r e dt op l a c e b og r o u p .I n
contrast, supplementation of vitamin C increased plasma
ascorbic acid signiﬁcantly in vitamin C group compared to
placebo group. At the same time, glycosylated hemoglobin
level decreased signiﬁcantly in vitamin C group compared
to placebo group (Table 4). No correlation existed between
plasma ascorbic acid and any of the parameters such as FBS,
PPBS, and HbA1c for both vitamin C and placebo group.
Of the seventy patients entered in the trial, four were
withdrawn (two in placebo group and two in vitamin C
group). The most common cause was failure to reattend;
one patient was dropped out in placebo group because of
uncontrolledbloodglucoselevelattheendoffourweeksand
was shifted to the other drug. No serious adverse event was
reported, and no abnormalities in laboratory test were found
during trial period.
4. Discussion
4.1. Vitamin C and DM. The primary ﬁnding of the present
study is a signiﬁcant decrease in FBG, PPBG, and HbA1c
Table 1: Demographic characteristics of patients with type 2
diabetes mellitus.
Variables Age (years) Sex
Male Female
Group A 48.33 ±1.39 15 18
Group B 45.88 ±1.42 13 20
P or χ2 P = 0.2219, d.f = 64 χ2 = 0.2481, d.f = 1
Pa >0.05 >0.05
Values are given as Mean ± SEM, n = 33 in each group, Group A: vitamin
C-treated group, Group B: placebo-treated group, aP values are ascertained
by unpaired t-test or χ2 test.
Table 2: Eﬀect of metformin with placebo on FBG, PPBG, HbA1c,
and plasma AA in patients with type 2 diabetes mellitus after 12
weeks of treatment.
Parameter Before
treatment After treatment P
(paired)
FBG 160.75 ±2.60 155.33 ±2.31 <0.05
PPBG 218.51 ±3.53 211.57 ±2.88 <0.05
HbA1c 8.18 ±0.12 8.01 ±0.11 >0.05
Plasma AA 0.24 ±0.006 0.27 ±0.01 >0.05
n = 33 in number, FBG: fasting blood glucose, PPBG: postmeal blood
glucose, HbA1c: glycosylated hemoglobin,plasma AA: plasma ascorbic acid.
FBG, PPBG, and plasma AA are measured in mg/dL.
Table 3: Eﬀect of metformin with vitamin C on FBG, PPBG,
HbA1c, and plasma AA in patients with type 2 diabetes mellitus
after 12 weeks of treatment.
Parameter Before
treatment After treatment P
(paired)
FBG 157.63 ±3.13 141.18 ±3.81 <0.01
PPBG 222.24 ±3.16 206.69 ±3.31 <0.05
HbA1c 8.26 ±0.09 7.80 ±0.08 <0.01
Plasma AA 0.26 ±0.008 0.45 ±0.01 <0.001
n = 33 in number, FBG: fasting blood glucose, PPBG: postmeal blood
glucose, HbA1c: glycosylated hemoglobin,plasma AA: plasma ascorbic acid.
FBG, PPBG, and plasma AA are measured in mg/dL.
and an increase in plasma ascorbic acid level after vitamin
C supplementation along with metformin in patients of
type 2 DM. To the best of our knowledge, this is the
ﬁrst report, related to signiﬁcant improvement in all above
parameters after concomitant use of metformin and vitamin
C. The results of this study are in agreement with previously
published data showing betterment in glycemic control with
vitamin C supplementation [10, 11]. In our study, patients
also received metformin and it is an established ﬁrst-line
drug for treatment of type 2 DM. Hence, it is diﬃcult to
say whether this beneﬁcial eﬀect of ascorbic acid supplement
could be attributed to its eﬀect on the underlying disease
or correction of the inadequate vitamin C status. The exact
mechanism by which vitamin C brings about these changes
is not known. It is well documented that there is an increased
production of damaging free radicals in type 2 DM patients.
Glucose autooxidation, protein glycosylation, formation of4 Advances in Pharmacological Sciences
Table 4: Comparison of eﬀects of metformin with vitamin C and
in combination with placebo on FBG, PPBG, HbA1c, and plasma
AA at 12 weeks in patients with type 2 diabetes mellitus taking into
account the change from baseline.
Parameter Change from baseline at 12 weeks P (unpaired)
Group A Group B
FBG −16.45 ±3.80 −5.42 ±2.65 <0.05
PPBG −15.54 ±2.42 −6.93 ±2.99 <0.05
HbA1c −0.451 ±0.07 −0.169 ±0.10 <0.05
Plasma AA 0.19 ±0.01 0.02 ± 0.01 <0.001
n = 33 in each group, Group A: vitamin C-treated group, Group B: placebo-
treated group, FBG: fasting blood glucose, PPBG: postmeal blood glucose,
HbA1c: glycosylated hemoglobin, plasma AA: plasma ascorbic acid. FBG,
PPBG, and plasma AA are measured in mg/dL.
advanced glycation end products, and polyol pathway are
involved in generation of oxidative stress, implicated in the
origin of both type 1 and 2 DM [12]. The protection against
such damage can be oﬀered by free radical-scavenging
antioxidants.
Increased demand for vitamin C to compensate the
increased oxidative stress and impaired transport or dietary
deﬁciency of vitamin C may be contributing to decreased
levels of plasma vitamin C levels observed in type 2 DM
patients [13]. High but physiologic concentrations of ascor-
bic acid can directly inhibit erythrocyte aldose reductase and
provide a rationale for the use of oral vitamin C supplements
in diabetes [14]. A signiﬁcant inverse relationship between
plasmaAAandDNAdamageintype2DMpatientsindicates
that poorly controlled diabetic subjects might beneﬁt from
increased dietary vitamin C [15]. Ascorbic acid supplemen-
tation for diabetic subjects may provide a simple means of
preventing and ameliorating the complications of diabetes.
The weak methodology in past research leads to conﬂicting
results as the studies were not controlled. Therefore, like
our trial, randomized, double-blind clinical trials of ascorbic
acid supplementation for longer duration should be a high
priority for establishment of role of ascorbic acid in diabetes.
Supplementation of vitamin C reduced FBG and HbA1c
levels in type 2 DM patients; it may be related to supple-
mentation of higher dose of vitamin C. In earlier study,
supplementation with 500mg/day vitamin C in diabetic
patients resulted in no changes in FBG and HbA1c in
comparison with placebo. This may be linked to low dose of
vitaminCusedinthisstudy[16].SupplementationofAAper
day for two weeks signiﬁcantly reduced erythrocyte sorbitol
and red cell sorbitol: plasma glucose (S/PG) ratio, and it was
concluded that 1,000mg AA per day supplementation might
provide a simple, safe, and eﬀective means of preventing
and ameliorating chronic complications of diabetes. But,
paradoxically the fasting plasma glucose levels revealed no
change. Shorter duration of study may be implicated for
this ﬁnding. Higher dose of AA provided improved glycemic
controlamongtype2DMsubjectsandbothFBGandHbA1c
improved [8]. Another study reported that AA may improve
glycemic control, lowering both FBG and HbA1c [17]. The
improvement of glycemic control was mainly initiated by a
beneﬁcialeﬀectofantioxidantonβcells.However,wecannot
totally deny the possibility that the antioxidant treatment
could have exerted an inﬂuence on target tissues other than
the β cells such as muscle and fat. Antioxidant treatment
has beneﬁcial eﬀects on preservation of β cell function in
diabetes, although the eﬀects may not be exerted totally
through its direct action on β cells. Also, regardless of the
inﬂuence on insulin sensitivity, the antioxidant treatment
indeed reduced blood glucose levels. Hence, vitamin C
reduced glucose toxicity and contributed in part to the
prevention of a decrease of β cell mass and insulin content.
Another explanation proposed for reduction of blood glu-
cose level is that plasma vitamin C levels seem to play a
role in the modulation of insulin action in diabetic subjects.
Vitamin C-mediated increase in insulin action is mainly due
toanimprovementinnonoxidativeglucosemetabolism[18].
Second most important observation of the study was
signiﬁcant reduction in HbA1c at twelve weeks in vitamin
C-supplemented group in comparison with placebo group.
But unfortunately, we could not ﬁnd signiﬁcant correlation
between plasma ascorbic acid and HbA1c at the baseline
and at twelve weeks. A signiﬁcant decrease was noted in
serum HbA1c in patients supplemented with vitamin C for
six weeks [19]. This could be attributed to competition of
vitamin C with glucose for reaction with amino groups
on the hemoglobin beta chain [20]. Further explanation
proposed that the increase of serum antioxidant glutathione
and the decrease of glycosylated hemoglobin after long-term
ascorbic acid supplementation are related to each other [21].
Our results do not rule out metabolic or pharmacokinetic
interactions between ascorbic acid and metformin. In either
case, results of the present study point to ascorbic acid
as critical in modulating biochemical eﬀects of metformin.
In previous studies, normal dietary vitamin C intake was
studied in detail but found to be of no use in diabetes
control and in reducing the risk of diabetes in future.
Many researchers used higher doses than normal dietary
intake of vitamin C and proved that higher doses will be
needed for glycemic control [22, 23]. In our study, nausea
and abdominal discomfort were reported in one patient in
placebo group while two patients in vitamin C group. These
patients were treated by the physician in medicine OPD.
All the patients responded to symptomatic treatment and
continued thestudy. No serious adverseeﬀects were reported
in the study.
4.2. Limitations. Though the study sample size is small and
duration is short, the value of results of the present study
cannot be taken away. However, studies with a larger sample
size and longer follow-up period together with measurement
of other related antioxidant levels may yield more meaning-
ful data on the role of the antioxidant system in the clinical
courseoftype2DM.Thereisaneedforincreasednumberof
follow-up visits to make this study more robust, broad-based
and representative of the Indian population. Further studies
on complicated and uncomplicated type 2 DM are required
to elucidate exact role of vitamin C supplementation in type
2D M .
4.3. Conclusion. Treatment with vitamin C with metformin
was well tolerated and devoid of any side eﬀects. The absence
of any substantial side eﬀects, cheaper cost, improvement inAdvances in Pharmacological Sciences 5
FBS, PPBS, and HBA1c, and the fact that plasma ascorbic
acid levels are decreased in DM and increased after oral
supplementation make it a particularly attractive therapeutic
adjuvant in the treatment of type 2 DM.
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